duloxetine teva
teva b.v. - duloksetinas - skrandyje neirios kietosios kapsulės - 60 mg; 30 mg - duloxetine
dulsevia
krka, d.d., novo mesto - duloksetinas - skrandyje neirios kietosios kapsulės - 60 mg; 30 mg - duloxetine
elify
medochemie ltd. - venlafaksinas - pailginto atpalaidavimo kietosios kapsulės - 150 mg; 37,5 mg; 75 mg - venlafaxine
fluoxetine vitabalans
vitabalans oy - fluoksetinas - plėvele dengtos tabletės - 20 mg - fluoxetine
flux
sandoz d.d. - fluoksetinas - kietosios kapsulės - 20 mg - fluoxetine
spitomin
egis pharmaceuticals plc - buspironas - tabletės - 10 mg; 5 mg - buspirone
amifampridine serb
serb sa - amifampridine phosphate - lambert-eaton myasthenic syndrome; paraneoplastic syndromes, nervous system; nervous system neoplasms; paraneoplastic syndromes; nervous system diseases; autoimmune diseases of the nervous system; neurodegenerative diseases; neuromuscular diseases; neuromuscular junction diseases; immune system diseases; autoimmune diseases; autoimmune diseases of the nervous system; cancer; neoplasms - kiti nervų sistemos vaistai - simptominis lambert-eaton myastheninio sindromo (lems) gydymas suaugusiesiems.
duloxetine mylan
mylan pharmaceuticals limited - duloksetinas - neuralgia; diabetic neuropathies; depressive disorder, major; anxiety disorders - psychoanaleptics, - gydant didžiosios depresijos sutrikimas;gydymo cukriniu diabetu periferinis neuropatinis skausmas;gydant generalizuoto nerimo sutrikimas;duloxetine mylan yra nurodyta suaugusieji.
methylthioninium chloride proveblue
provepharm sas - metiltioninio chlorido - methemoglobinemija - visi kiti gydomieji produktai - Ūminis vaistų ir cheminių preparatų sukelto methemoglobinemijos simptominis gydymas. methylthioninium chloridas proveblue yra nurodyta suaugusiesiems, vaikams ir paaugliams (amžius 0 iki 17 metų amžiaus).
xtandi
astellas pharma europe b.v. - enzalutamidas - prostatos navikai - endokrininė terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.